Specific subsets of mesenchymal stroma cells to treat lung disorders - Finding the Holy Grail.

Summary, in English

Accumulating studies, both in animals and human clinical trials with mesenchymal stroma cells (MSC) support the hypothesis of therapeutic effects of these cells in various disorders. However, despite success in immune-mediated disorders such as Crohns' disease, lung disorders such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary disease (IPF) treated with MSC have so far not yielded a revolutionary effect on clinical symptoms. Promising data on immunomodulatory effects in COPD have kept nourishing the research into finding specific traits of MSC beneficial in disease. A heterogeneous population of injected cells might drown a potential therapeutic role of a specific group of MSC. Thus careful analysis of MSC regarding their molecular capabilities such as delivering specific therapeutic vesicles to the environment, or plain cytokine/chemokine fingerprinting might prove useful in augmenting therapies against lung diseases.

• Author: Sara Rolandsson Enes; Jenny C Karlsson; Stefan Scheding; Gunilla Westergren-Thorsson
• Department/s: Lung Biology; Stem Cell Center; StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
• Publishing year: 2014
• Language: English
• Pages: 93-95
• Publication/Series: Pulmonary Pharmacology & Therapeutics
• Volume: 29
• Issue: 2
• Full text: - 220 kB; Download statistics
• Links: http://www.ncbi.nlm.nih.gov/pubmed/25239767?dopt=Abstract; http://dx.doi.org/10.1016/j.pupt.2014.08.001
• Document type: Journal article review
• Publisher: Elsevier
• Topic: Cell and Molecular Biology
• Status: Published
• Research group: Lung Biology
• ISBN/ISSN/Other: ISSN: 1522-9629